Tag:
Charles River
Latest Headlines
Latest Headlines
Charles River and Metabolon partner to advance oncology research for others
What should one of the country's largest CROs do when it wants to beef up its work in oncology research? Call up Metabolon.
Charles River sees signs of growth in latest assessment
The latest set of numbers from Boston-based Charles River Laboratories ( $CRL ) is getting a thumbs-up from analysts happy to see signs of stability on the business front. The preclinical study experts
CROs jump into 2012 with big contracting momentum
Over the past few years the clinical research organization side of the industry has been undergoing a steady shakeout of small players as the big CROs lined up long-term deals with drug developers....
Charles River in rumored negotiations with 'undisclosed suitor'
Uh-oh. An "undisclosed suitor" or others may be in talks with Charles River Laboratories ( $CRL ) in a deal that could split the life sciences contract research organization in two, or sell off those
Charles River posts Q4 loss on preclinical writedown
A steep write-down related to its preclinical services business pushed Charles River Laboratories to a fourth-quarter loss, but adjusted results still exceeded Wall Street's expectations. Report
Charles River Labs ready to shed assets in earnings drive
With reports circulating that a pair of its big investors are prodding the managers of Charles River Laboratories to put the company up for sale , the CRO today outlined plans to shed itself of some
WSJ: Big investors pushing Charles River ($CRL) toward the auction block
Two of Charles River Laboratories' ( $CRL ) biggest investors are maneuvering behind the scenes to push the big CRO onto the auction block, according to a report in the Wall Street Journal. Quoting
CRO Charles River ($CRL) cuts 300 more jobs
Facing a continued decline in sales, CRO Charles River ( $CRL ) said it will cut 4 percent of is 8,500-person workforce, or about 300 jobs. This is not the first time the CRO announced layoffs in 2010.
Charles River, WuXi call off $1.6B deal
Shareholder opposition has forced Charles River to call off its $1.6 billion plan to purchase China's WuXi PharmaTech. Despite CEO James Foster's assurances that the deal would bring up to $100
Charles River sweetens WuXi merger with 'synergies'
Faced with some stiff opposition from investors arrayed against a proposed $1.6 billion merger of Charles River Laboratories and China's WuXi PharmaTech, the Massachusetts-based CRO is baiting its
